Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced preliminary, unaudited fourth quarter and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results